NomosLogic

Media Coverage

NomosLogic in the Press

Coverage, publications, and media mentions from leading industry outlets.

Fidelity Investments

Fidelity Investments: NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite

Lyceum is the first personalized genomic literacy quiz built from your own DNA. The questions are not generic trivia. Every question is generated from your own genome, your own pharmacogenomic profile, your own ancestral signal, and your own multi-omic context. After you answer, Chiron, NomosLogic’s AI health agent, steps in as your tutor and explains the science in plain language.

October 1, 2026Read Article

FinancialContent.com

NomosLogic Brings Deterministic Molecular Medicine Infrastructure to BIO International Convention 2026 as Adverse Drug Reactions Continue to Cost $30 Billion and 100,000 American Lives Each Year

NomosLogic, Inc., a deterministic molecular medicine infrastructure company headquartered in Salt Lake City, announced today that the company will be present at the 2026 BIO International Convention from June 22 to 25 at the San Diego Convention Center. Founder and CEO Matthew Hardy and SVP of Business Development Jai DeJong will be available for one-to-one meetings through BIO Partnering and open conversations with payer organizations, biopharmaceutical partners, clinical point of care and investors throughout the convention. The company will share the BioUtah exhibitor pavilion.

May 25, 2026Read Article

BioUtah

Bio Utah Growth Zone

NomosLogic is a Salt Lake City-based clinical genomics infrastructure company. The platform delivers deterministic, audit-ready interpretation across genomic, chemistry, hematology, and pharmacogenomic data, returning structured clinical decisions in seconds. NomosLogic is building the infrastructure layer that the next decade of precision medicine will run on.

May 21, 2026Read Article
AI Invest

AI Invest

NomosLogic Challenges Probabilistic Consensus With Deterministic Genomic Engine

NomosLogic is not selling a drug or a test. It is building the fundamental rails for a paradigm shift in molecular medicine. The company operates as an infrastructure layer, a foundational platform designed to transform the raw data already sitting in health systems and consumer genomics platforms into clinically actionable intelligence. This is the critical gap: the data already exists. What has been missing is the molecular medicine layer that deterministically turns data into medication guidance and usable health intelligence.

May 21, 2026Read Article
MorningStar

MorningStar

NomosLogic Introduces Molecular Medicine Infrastructure for Consumer Genomics, Multi-Omic Fusion, and Deterministic Disease Modeling

The first consumer experiences powered by true molecular medicine infrastructure are now live at lite.dendrite.com. Take a quiz built from your own genome. Read the seven-chapter story of your biology. Then bring your family.

May 21, 2026Read Article

BriefGlance

Beyond Probability: A New Framework to Rebuild Personalized Medicine

For decades, the promise of genomics has been tantalizingly simple: sequence a person’s DNA to predict their disease risk and tailor treatments accordingly. Yet for most complex, multi-gene diseases like diabetes, heart disease, and autoimmune disorders, this promise has remained largely unfulfilled. The field has produced vast lists of genetic variants associated with slight increases in risk, but these probabilistic scores often lack direct clinical utility and fail to explain why one person with a specific risk profile gets sick while another remains healthy.

May 6, 2026Read Article
Associated Press

Associated Press

NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite

If you have ever stared at a generic DNA report and thought “I have no idea what any of this actually means for me,” Lyceum is the answer. It teaches you the language of your own biology, one question at a time.

May 3, 2026Read Article
Yahoo Finance

Yahoo Finance

NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite

"This is the moment I have been building toward for thirty years," said Matthew Hardy, Founder and CEO of NomosLogic. "We did not build a quiz app. We built molecular medicine infrastructure that translates across more than forty nomenclature systems, fuses multi-omic data, and resolves a whole genome in under 130 seconds. Lyceum and Odyssey are what happens when that infrastructure points itself directly at the patient. For the first time in consumer genomics, a quiz can ask you about your own genome and actually be right. That is not a feature. That is a category change."

May 3, 2026Read Article
AI Invest

AI Invest

NomosLogic Challenges Probabilistic Consensus With Deterministic Genomic Engine

This deterministic approach stands in stark contrast to the current probabilistic paradigm. Today's models often struggle with the complexity of human genetics, leaving a significant gap between observed heritability and what can be explained by known variants. The evidence for this "data-to-intelligence gap" is clear in the case of schizophrenia, where the SNP-heritability of schizophrenia was 24.4%. This figure, derived from large-scale studies, highlights the disconnect between the known genetic contribution to disease and the actionable insights that can be generated from current data interpretation methods. NomosLogic's platform is explicitly designed to bridge this gap, moving from probabilistic associations to deterministic clinical logic.

May 3, 2026Read Article

Santa Maria Times

Matthew L. Hardy, Founder and CEO of NomosLogic Inc., Announces Deterministic Convergence, a New Book Introducing a Systems-Architecture Framework for Understanding Complex Biology

“Deterministic Convergence” examines why current methods often succeed in monogenic disease but struggle with complex disease, drug discovery, population portability, and individualized care. The book presents a framework for interpreting biology as architecture, with implications for clinical decision-making, therapeutic targeting, ancestry-aware analysis, and personalized intervention design.

April 30, 2026Read Article

Associated Press

Matthew L. Hardy, Founder and CEO of NomosLogic Inc., Announces Deterministic Convergence, a New Book Introducing a Systems-Architecture Framework for Understanding Complex Biology, Personalized Medicine, and the Limits of Probability-Based Genomics

“Deterministic Convergence” examines why current methods often succeed in monogenic disease but struggle with complex disease, drug discovery, population portability, and individualized care. The book presents a framework for interpreting biology as architecture, with implications for clinical decision-making, therapeutic targeting, ancestry-aware analysis, and personalized intervention design.

April 30, 2026Read Article

BusinessWire

Matthew L. Hardy, Founder and CEO of NomosLogic Inc., Announces Deterministic Convergence, a New Book Introducing a Systems-Architecture Framework for Understanding Complex Biology, Personalized Medicine, and the Limits of Probability-Based Genomics

“Deterministic Convergence” examines why current methods often succeed in monogenic disease but struggle with complex disease, drug discovery, population portability, and individualized care. The book presents a framework for interpreting biology as architecture, with implications for clinical decision-making, therapeutic targeting, ancestry-aware analysis, and personalized intervention design.

April 30, 2026Read Article

Mark8Access

Mark8Access-NomosLogic Launches Molecular Medicine Infrastructure

NomosLogic has introduced a new molecular medicine infrastructure designed for consumer genomics, integrating multi-omic data with deterministic disease modeling. The platform aims to enhance precision health insights by combining genomics, proteomics, and other biological datasets into a unified system. This advancement is positioned to improve early disease prediction, personalized treatment strategies, and scalable health analytics for both individuals and healthcare providers.

April 15, 2026Read Article

ADVFN

ADVFN - NomosLogic Introduces Molecular Medicine Infrastructure for Consumer Genomics, Multi-Omic Fusion, and Deterministic Disease Modeling

The platform is protected by a broad patent portfolio spanning nomenclature resolution, deterministic clinical logic architecture, multi-omic fusion, evolutionary simulation, and state-faithful systems visualization. NomosLogic is currently in active clinical validation and partnership discussions across consumer genomics, payer, and pharmaceutical markets.

April 14, 2026Read Article

Caledonian Record

Caledonian Record - NomosLogic Clinical Genomics Infrastructure

NomosLogic, Inc. today introduced its molecular medicine infrastructure platform, designed to transform raw genomic files into clinically actionable intelligence across pharmacogenomics, disease susceptibility, and systems-level health modeling.

April 14, 2026Read Article

Rutland Herald

Rutland Herald - NomosLogic

NomosLogic is building infrastructure for molecular medicine. The company's platform integrates deterministic genomic interpretation, multi-omic fusion, distributed disease modeling, patient-facing insight generation, and governance-grade auditability into a unified infrastructure layer for health systems, consumer genomics platforms, payers, and biopharma.

April 13, 2026Read Article

Times Argus

Times Argus - NomosLogic Introduces Molecular Medicine Infrastructure for Consumer Genomics, Multi-Omic Fusion, and Deterministic Disease Modeling

Consumer genomics platforms, health systems, health plans, and biopharma organizations already sit on enormous genomic and clinical data assets. What is missing is the infrastructure layer that makes those assets clinically usable.

April 13, 2026Read Article

Joplin Globe

Joplin Globe - Genomics has never really had an interpretation problem at the level of data availability. It has had an infrastructure problem.

“Genomics has never really had an interpretation problem at the level of data availability. It has had an infrastructure problem. The data already exists. What has been missing is the molecular medicine layer that can deterministically turn that data into medication guidance, disease architecture, and health intelligence that people can actually use.”

April 13, 2026Read Article

Bakersfield.com

Bakersfield.com - NomosLogic operates as an infrastructure layer for molecular medicine rather than a point product

NomosLogic, Inc. today introduced its molecular medicine infrastructure platform, designed to transform raw genomic files into clinically actionable intelligence across pharmacogenomics, disease susceptibility, and systems-level health modeling.

April 13, 2026Read Article

GenomeWeb

GenomeWeb - NomosLogic Dendrite Lite, Clinical Standalone

NomosLogic has launched Dendrite Lite, a genomic health platform for consumers that provides pharmacogenomic findings to individuals with DNA data, and Clinical Standalone engine for health systems and clinical partners. According to the Utah-based company, the platforms provide "deterministic output" – findings that are reproducible, auditable, and traceable to evidence – along with clinical-grade evidence. Its Dendrite Lite consumer platform, which costs $99, $149, or $249 depending on the tier selected, accepts DNA files from 23andMe, AncestryDNA, and MyHeritage and generates a report in about 2 minutes.

April 13, 2026Read Article

BussinessWire

BusinessWire - NomosLogic launched molecular medicine infrastructure for deterministic genomic interpretation, multi-omic fusion, and disease modeling.

The data already exists. What has been missing is the molecular medicine layer that deterministically turns data into medication guidance and usable health intelligence.

April 13, 2026Read Article

Morningstar

Morningstar Press Release - NomosLogic Introduces Molecular Medicine Infrastructure for Consumer Genomics, Multi-Omic Fusion, and Deterministic Disease Modeling

NomosLogic is building infrastructure for molecular medicine. The company's platform integrates deterministic genomic interpretation, multi-omic fusion, distributed disease modeling, patient-facing insight generation, and governance-grade auditability into a unified infrastructure layer for health systems, consumer genomics platforms, payers, and biopharma.

April 13, 2026Read Article

Yahoo Finance

Yahoo Finance - NomosLogic Introduces Molecular Medicine Infrastructure for Consumer Genomics, Multi-Omic Fusion, and Deterministic Disease Modeling

Consumer genomics platforms, health systems, health plans, and biopharma organizations already sit on enormous genomic and clinical data assets. What is missing is the infrastructure layer that makes those assets clinically usable.

April 13, 2026Read Article

AP Press

AP Press - NomosLogic Introduces Molecular Medicine Infrastructure for Consumer Genomics, Multi-Omic Fusion, and Deterministic Disease Modeling

“Genomics has never really had an interpretation problem at the level of data availability. It has had an infrastructure problem. The data already exists. What has been missing is the molecular medicine layer that can deterministically turn that data into medication guidance, disease architecture, and health intelligence that people can actually use.”

April 13, 2026Read Article